RITUXAN HYCELA: SAME ANTIBODY AS RITUXAN® (rituximab), DELIVERED SUBCUTANEOUSLY WITH HYALURONIDASE HUMAN 1

RITUXAN HYCELA is a combination of rituximab and hyaluronidase human

  • Rituximab: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis
  • Hyaluronidase human: Hyaluronidase human increases the permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan, a polysaccharide found in the extracellular matrix of the subcutaneous tissue

HOW IS RITUXAN HYCELA THOUGHT TO WORK? 1

  • RITUXAN HYCELA is administered by subcutaneous injection into the abdomen
  • Hyaluronidase human increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan, based on preclinical studies
  • Hyaluronidase human has been shown to increase the absorption rate of rituximab into the systemic circulation when given in the subcutaneous tissue, based on preclinical studies
  • In the doses administered, hyaluronidase human in RITUXAN HYCELA acts locally
  • The effects of hyaluronidase human are reversible and permeability of the subcutaneous tissue is restored within 24-48 hours

Based on preclinical studies, possible mechanisms of rituximab cell lysis include:

  • Complement-dependent cytotoxicity (CDC)
  • Antibody-dependent cell-mediated cytotoxicity (ADCC)